Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia-Reference-Cited by-同舟云学术

Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia

Published:2022-03-17 Issue:11 Volume:139 Page:1766-1770
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Bewersdorf Jan Philipp¹²³,Patel Kishan K.¹²^ORCID,Goshua George¹⁴,Shallis Rory M.¹²^ORCID,Podoltsev Nikolai A.¹²^ORCID,Huntington Scott F.¹²^ORCID,Zeidan Amer M.¹²

Affiliation:

1. Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, and

2. Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT;

3. Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY; and

4. Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

https://ashpublications.org/blood/article-pdf/139/11/1766/1881980/bloodbld2021014401.pdf

Reference21 articles.

1. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia;Lancet;J Clin Oncol.,2018

2. CPX-351 versus 7 + 3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial;Lancet;Lancet Haematol.,2021

3. Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia;Villa;J Med Econ.,2020

4. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia;Patel;Blood Adv.,2021

5. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves;Guyot;BMC Med Res Methodol.,2012

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liposomal drug formulations for treatment of hematological malignancies;Expert Opinion on Pharmacotherapy;2023-10-17

2. Paradigm Shift in the Management of Acute Myeloid Leukemia—Approved Options in 2023;Cancers;2023-05-31

3. Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?;Journal of the National Comprehensive Cancer Network;2023-05

4. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia;Leukemia & Lymphoma;2022-12-09

5. Nanoengineered, magnetically guided drug delivery for tumors: A developmental study;Frontiers in Chemistry;2022-10-04